On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.
about
Impact of cardiac magnetic resonance imaging in non-ischemic cardiomyopathiesReview of Journal of Cardiovascular Magnetic Resonance 2012.Review of Journal of Cardiovascular Magnetic Resonance 2011.Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.Targeting chelatable iron as a therapeutic modality in Parkinson's disease.Novel frataxin isoforms may contribute to the pathological mechanism of Friedreich ataxiaEffects of blood transfusion on exercise capacity in thalassemia major patients.T1 at 1.5T and 3T compared with conventional T2* at 1.5T for cardiac siderosis.Treating thalassemia major-related iron overload: the role of deferiprone.Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspectiveA 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).Iron chelation therapy in the management of transfusion-related cardiac iron overload.Regional siderosis: a new challenge for iron chelation therapy.Iron metabolism in transplantation.Biology of ferritin in mammals: an update on iron storage, oxidative damage and neurodegeneration.Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions.Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.Cardiac complications in beta-thalassemia: From mice to men.The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major-intermedia dichotomy?Current recommendations for chelation for transfusion-dependent thalassemia.Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.Chelation therapy in cardiovascular disease: an update.Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromesThe effect of metoprolol succinate on the cardiac function of patients with thalassaemia cardiomyopathy: a double-blind randomised study.Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.Getting to the "Heart" of Cardiac Disease by Decreasing Mitochondrial Iron.Cardiac iron measurement and iron chelation therapy in patients with β thalassaemia major: experience from Taiwan.Management of cardiac hemochromatosis.
P2860
Q26765173-420A1743-9A2E-4246-AB14-9ECC625E302DQ30446298-4BA26CEE-A8B9-4322-830E-0F5D4CE28773Q30459937-9ADA9F5D-0E7B-4742-82F3-AE5A82B8DE8FQ33407282-DEBB07C1-1362-4545-8CDC-A0CB450A1EDBQ33768106-69420247-6A62-48D1-B612-8412D8373FE6Q34452330-A4608CE5-D7C6-4C51-B39C-2190AA4504E0Q35641346-7A70F1A3-F3BD-436D-8375-E5D87EDB4FF6Q36318293-A026F648-A8BA-452D-8E24-517AB85F7DC7Q36344669-6861589B-C6EA-486F-B325-9AF9BED034A5Q37132320-F22072B6-978F-44EE-B04A-70723BD6109FQ37623523-91A4272D-74F0-48E9-9D3F-FA62962EF8F4Q37992181-ED03089F-69F0-4CF6-B336-F1FC79AF20F9Q38178660-76A43B67-1A7F-4893-9CE1-00D51B8132FAQ38223148-7170A209-756F-492F-A761-3E1E31976EC2Q38239577-EE401FE2-69C6-44CC-8E1E-248DB9800B5EQ38540491-DE2DB237-C1CE-4D7D-9EDE-429CE0BBA427Q38650293-7046261A-57B4-4198-BDF7-30F7628B5F05Q38686059-DB82E5AB-5EE7-4681-A790-9C23F55F8DE2Q38810873-6BEF02D9-8158-471E-9A57-66FD6C3ABEDBQ38836184-ADB870C6-6D61-44D3-852B-C3DAD6A9DB25Q38968558-5DE7E7F4-9693-47E0-84F8-D565CE931AD5Q39361634-145D2D0A-2C13-4E55-9C61-24704DDF2ABDQ39453693-6FBDCC0E-F100-4B22-A898-51FFBA3DCE83Q40209714-FCD5A0B8-0749-4AD3-A7D7-E71E1E3DA813Q42183463-92E18C78-7367-41E4-AC31-84E3CE627F5EQ43288665-B71F7E90-89A8-4A17-9F14-1B2DA6115BA8Q44142481-1D11C9CD-C6D6-4E11-977B-C74034E94FEFQ55230811-692E0F59-B0AE-499C-93C5-684E1997321F
P2860
On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
On improvement in ejection fra ...... risk of future heart failure.
@ast
On improvement in ejection fra ...... risk of future heart failure.
@en
type
label
On improvement in ejection fra ...... risk of future heart failure.
@ast
On improvement in ejection fra ...... risk of future heart failure.
@en
prefLabel
On improvement in ejection fra ...... risk of future heart failure.
@ast
On improvement in ejection fra ...... risk of future heart failure.
@en
P2093
P2860
P356
P1476
On improvement in ejection fra ...... risk of future heart failure.
@en
P2093
D J Pennell
J P Carpenter
M Roughton
Zi Cabantchik
P2860
P2888
P356
10.1186/1532-429X-13-45
P577
2011-09-12T00:00:00Z
P5875
P6179
1020738261